ANNX Annexon, Inc.
QT34| Index | — | P/E | — | EPS (ttm) | -1.16 | Insider Own | 15.13% | Shs Outstand | 163.84M | Perf Week | 6.49% |
| Market Cap | 645.54M | Forward P/E | — | EPS next Y | -0.99 | Insider Trans | 2.61% | Shs Float | 175.57M | Perf Month | -5.97% |
| Enterprise Value | 458.54M | PEG | — | EPS next Q | -0.28 | Short Float | — | Perf Quarter | -26.08% | ||
| Income | -202.00M | P/S | — | EPS this Y | — | Short Ratio | 11.03 | Perf Half Y | -30.76% | ||
| Sales | 0.00 | P/B | 3.47 | EPS next Y | — | ROA | -82.36% | Short Interest | 31.63M | Perf YTD | -21.51% |
| Book/sh | 1.14 | P/C | 3.09 | EPS next 5Y | — | ROE | -106.15% | 52W High | 7.18 -45.13% | Perf Year | 34.47% |
| Cash/sh | 1.28 | P/FCF | — | EPS past 3/5Y | — | ROIC | -99.93% | 52W Low | 2.54 55.12% | Perf 3Y | 90.34% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.84% 6.22% | Perf 5Y | -77.41% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.24 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 5.53 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 48.88 | Recom | 2.09 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.53 | EPS Q/Q | 17.65% | SMA20 | 1.95% | Beta | 1.38 | Target Price | 10.50 |
| Payout | 0.00% | Debt/Eq | 0.12 | Sales Q/Q | — | SMA50 | -5.78% | Rel Volume | 0.73 | Prev Close | 4.05 |
| Employees | 92 | LT Debt/Eq | 0.12 | Earnings | Nov 09 | SMA200 | -24.36% | Avg Volume | 3.14M | Price | 3.94 |
| IPO Date | Jul 24, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -17.23% — | Net Debt/EBITDA | — | Volume | 2,276,667 | Change | -2.72% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Upgrade | Citizens | Market Underperform → Market Perform | |
| Jul-20-26 | Reiterated | H.C. Wainwright | Buy | $14 |
| May-12-26 | Initiated | Goldman Sachs | Neutral | $7.00 |
| Dec-23-25 | Initiated | Chardan | Buy | |
| Jun-05-24 | Reiterated | Wells Fargo | Overweight | $10 → $14 |
| May-15-24 | Reiterated | Wells Fargo | Overweight | $12 → $10 |
| Apr-01-24 | Reiterated | Wells Fargo | Overweight | $12 |
| Mar-27-24 | Reiterated | Wells Fargo | Overweight | $12 |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight | |
| Dec-21-23 | Upgrade | B of A Securities | Neutral → Buy |
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2 | 4 | 3 | 0 | — | — | — | — | — | |
| Gross Profit | -2 | -4 | -3 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 36 | 32 | 35 | 28 | — | — | — | — | — | |
| Research and Development | 176 | 185 | 119 | 114 | — | — | — | — | — | |
| Other Operating Expense | -4 | -4 | -3 | 2 | — | — | — | — | — | |
| Operating Income | -210 | -216 | -154 | -144 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 10 | 16 | 9 | — | — | — | — | — | |
| Net Income Before Taxes | -202 | -207 | -138 | -134 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -202 | -207 | -138 | -134 | — | — | — | — | — | |
| Net Income From Continuing Operations | -202 | -207 | -138 | -134 | — | — | — | — | — | |
| Net Income | -202 | -207 | -138 | -134 | — | — | — | — | — | |
| EPS (Recurring) | -1.16 | -1.34 | -1.01 | -1.77 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.16 | -1.34 | -1.01 | -1.77 | — | — | — | — | — | |
| EPS (Diluted) | -1.16 | -1.34 | -1.01 | -1.77 | — | — | — | — | — | |
| EBITDA | -201 | -205 | -136 | -132 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 201 | 155 | 137 | 76 | — | — | — | — | — | |
| Market Capitalization | 792 | 778 | 703 | 345 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Love Douglas | PRESIDENT AND CEO | Sep 24 '26 | Buy | 3.83 | 26,065 | 99,829 | 390,476 | Sep 25 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Jun 11 '26 | Option Exercise | 1.85 | 30,646 | 56,698 | 184,807 | Jun 15 |
| Satter Muneer A | Director | May 28 '26 | Buy | 5.41 | 613,497 | 3,319,019 | 10,342,134 | May 29 |
| Carson William H. | Director | May 11 '26 | Buy | 5.78 | 8,000 | 46,240 | 78,405 | May 13 |
| Carson William H. | Director | Apr 10 '26 | Buy | 6.20 | 8,000 | 49,600 | 70,405 | Apr 14 |
| Carson William H. | Director | Mar 10 '26 | Buy | 5.67 | 8,000 | 45,360 | 62,405 | Mar 12 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | Mar 02 '26 | Sale | 5.43 | 5,820 | 31,603 | 123,582 | Mar 04 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Mar 02 '26 | Sale | 5.42 | 4,339 | 23,517 | 182,625 | Mar 04 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Mar 02 '26 | Sale | 5.42 | 5,566 | 30,168 | 154,161 | Mar 04 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Mar 02 '26 | Sale | 5.43 | 5,894 | 32,004 | 180,093 | Mar 04 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Mar 02 '26 | Sale | 5.42 | 5,565 | 30,162 | 170,700 | Mar 04 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | Feb 18 '26 | Sale | 5.10 | 5,290 | 26,979 | 73,152 | Feb 20 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 18 '26 | Sale | 5.11 | 7,851 | 40,119 | 113,765 | Feb 20 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Feb 18 '26 | Sale | 5.10 | 5,290 | 26,979 | 123,487 | Feb 20 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 18 '26 | Sale | 5.11 | 7,857 | 40,149 | 97,227 | Feb 20 |